- Home
- MUA vs YMAB Comparison
MUA vs YMAB Comparison
Compare MUA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- YMAB
- Stock Information
- Founded
- MUA 1993
- YMAB 2015
- Country
- MUA United States
- YMAB United States
- Employees
- MUA N/A
- YMAB N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- YMAB Health Care
- Exchange
- MUA Nasdaq
- YMAB Nasdaq
- Market Cap
- MUA 474.4M
- YMAB 482.4M
- IPO Year
- MUA N/A
- YMAB 2018
- Fundamental
- Price
- MUA $10.99
- YMAB $8.28
- Analyst Decision
- MUA
- YMAB Strong Buy
- Analyst Count
- MUA 0
- YMAB 10
- Target Price
- MUA N/A
- YMAB $21.00
- AVG Volume (30 Days)
- MUA 92.6K
- YMAB 303.4K
- Earning Date
- MUA 01-01-0001
- YMAB 11-08-2024
- Dividend Yield
- MUA 4.84%
- YMAB N/A
- EPS Growth
- MUA N/A
- YMAB N/A
- EPS
- MUA N/A
- YMAB N/A
- Revenue
- MUA N/A
- YMAB $84,553,000.00
- Revenue This Year
- MUA N/A
- YMAB $6.46
- Revenue Next Year
- MUA N/A
- YMAB $20.68
- P/E Ratio
- MUA N/A
- YMAB N/A
- Revenue Growth
- MUA N/A
- YMAB N/A
- 52 Week Low
- MUA $8.61
- YMAB $6.29
- 52 Week High
- MUA $11.43
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- MUA 21.79
- YMAB 25.63
- Support Level
- MUA $11.70
- YMAB $9.31
- Resistance Level
- MUA $11.90
- YMAB $11.10
- Average True Range (ATR)
- MUA 0.20
- YMAB 0.72
- MACD
- MUA -0.09
- YMAB -0.09
- Stochastic Oscillator
- MUA 3.10
- YMAB 7.35
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.